Hanna F W, Pettit R J, Ammari F, Evans W D, Sandeman D, Lazarus J H
Department of Medicine, University of Wales College of Medicine, Cardiff, UK.
Clin Endocrinol (Oxf). 1998 Feb;48(2):229-34. doi: 10.1046/j.1365-2265.1998.3871200.x.
Hyperthyroidism is associated with a reduction in bone mineral density (BMD). Suppressive doses of thyroxine (T4), inducing subclinical hyperthyroidism, have been reported by some investigators to reduce BMD. Little work has been done on replacement doses of T4.
The aim was to investigate the effect of replacement doses of T4 on BMD.
Cross-sectional study of hypothyroid patients on long-term T4 replacement doses, comparing those who had primary hypothyroidism with those who were previously hyperthyroid.
Fifty women on replacement doses of T4 for more than 5 years were recruited. Twenty-five were treated for primary (group 1) and 25 for radioiodine-induced hypothyroidism (group 2). They were well matched for age, menstrual status, smoking history, body mass index (BMI), dose and duration of T4 replacement as well as thyroid status.
BMD was assessed by dual energy X-ray absorptiometry. Free T4 (FT4), FT3 as well as ultrasensitive TSH assays were used to assess thyroid status.
The two groups showed no difference in BMD (g/cm2) of the lumbar spine (1.008 vs. 0.957, P = 0.25), femoral neck (0.745 vs. 0.735, P = 0.79) and total hip (0.878 vs. 0.837, P = 0.24). When the two groups were pooled, there was no significant difference between the patients and a reference population with femoral neck and total hip BMD expressed as a standard deviation (Z) score. However, the lumbar spine mean Z score was significantly greater than zero. For each site, there was a negative correlation of BMD with age in at least one group but, in general, BMI, FT4, FT3 and duration of T4 replacement did not correlate with BMD. T4 dose, however, had a consistent positive correlation with BMD in the spine, femoral neck and the hip (P = 0.01, 0.04 and 0.02, respectively) in group 2 but not group 1.
In this study, there is no evidence for a difference in bone mineral density in patients receiving replacement doses of thyroxine irrespective of the aetiology of their hypothyroidism. The reduced bone mineral density associated with hyperthyroidism appears to be restored, maintained and in some cases possibly improved while on long-term thyroxine replacement post-radioiodine.
甲状腺功能亢进与骨密度(BMD)降低有关。一些研究者报告称,抑制剂量的甲状腺素(T4)可导致亚临床甲状腺功能亢进,进而降低骨密度。关于T4替代剂量的研究较少。
旨在研究T4替代剂量对骨密度的影响。
对接受长期T4替代剂量的甲状腺功能减退患者进行横断面研究,比较原发性甲状腺功能减退患者和既往甲状腺功能亢进患者。
招募了50名接受T4替代剂量超过5年的女性。其中25名接受原发性甲状腺功能减退治疗(第1组),25名接受放射性碘诱导的甲状腺功能减退治疗(第2组)。她们在年龄、月经状况、吸烟史、体重指数(BMI)、T4替代剂量和持续时间以及甲状腺状态方面匹配良好。
采用双能X线吸收法评估骨密度。使用游离T4(FT4)、FT3以及超敏TSH测定来评估甲状腺状态。
两组在腰椎骨密度(g/cm2)(1.008对0.957,P = 0.25)、股骨颈(0.745对0.735,P = 0.79)和全髋(0.878对0.837,P = 0.24)方面无差异。将两组合并后,患者与以标准差(Z)评分表示的股骨颈和全髋骨密度参考人群之间无显著差异。然而,腰椎平均Z评分显著大于零。对于每个部位,至少在一组中骨密度与年龄呈负相关,但总体而言,BMI、FT4、FT3和T4替代持续时间与骨密度无相关性。然而,在第2组中,T4剂量与脊柱、股骨颈和髋部的骨密度呈一致的正相关(分别为P = 0.01、0.04和0.02),而在第1组中并非如此。
在本研究中,无论甲状腺功能减退的病因如何,接受甲状腺素替代剂量的患者在骨密度方面没有差异的证据。与甲状腺功能亢进相关的骨密度降低在放射性碘治疗后的长期甲状腺素替代治疗期间似乎得到恢复、维持,在某些情况下可能有所改善。